Heart Disease Trial, Recruiting NCT06365502 Sponsor: Harbin Medical University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06365502
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years of age
  • People who have had a heart attack or severe chest pain (unstable angina) and are planned to have a procedure to open blocked arteries (called PCI, or percutaneous coronary intervention)
  • People who have had stents successfully placed in the main blocked artery or arteries causing their symptoms, with less than 20% blockage remaining after the procedure
  • People who have at least one other artery with a moderate blockage (40–80% narrowed) that has been assessed using a special blood flow measurement tool and found not to be severely restricting blood flow
  • The artery being studied (the "target" artery) must be of a certain size — between 2.0 and 4.0 mm wide and no more than 50 mm in the blocked section
  • The target artery must meet at least two specific imaging criteria that suggest the artery wall has features considered higher risk, as assessed by specialised internal imaging of the artery (confirm with trial site for full details)
  • People who have given written consent to participate before any study procedures begin

Who may not be able to join:

  • People who have a known allergy or intolerance to any of the study medications or device materials — including aspirin, certain blood-thinning medicines, or paclitaxel — that cannot be managed with pre-treatment
  • People who are on medicines that suppress the immune system, or who have a serious immune system condition (such as HIV or lupus) requiring ongoing immune-suppressing treatment
  • People who have dangerously low blood pressure, are in shock, or need special machines or medicines to support their heart and blood pressure
  • People with significantly reduced kidney function (confirm specific threshold with trial site)
  • People whose heart is pumping with less than 30% of its normal strength, based on an imaging test done within 30 days before the procedure
  • People whose life expectancy is less than 2 years for any reason
  • People who are currently taking part in another clinical trial of an experimental drug or device that has not yet finished collecting its main results
  • People who have other health, social, or psychological conditions that the trial doctors believe could affect their ability to participate fully or follow up as required
  • People whose target artery blockage is located within 10 mm of a previously placed stent (either side)
  • People whose target blockage is in the left main coronary artery (the main large artery supplying the heart)
  • People whose target blockage is at a point where an artery branches off, if the branch vessel is larger than 2 mm and more than 50% narrowed
  • People whose target artery has severe calcium build-up or a very winding, curved shape
  • People whose target blockage is within 3 mm of the point where certain major heart arteries begin (the openings of the LAD, LCX, or RCA arteries)
  • People whose target blockage is inside a bypass graft artery (an artery placed during previous bypass surgery)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bo Yu, PhD, The Second Affiliated Hospital of Harbin Medical University

Phone: 15945685291

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Harbin Medical University
Registry
ClinicalTrials.gov
Start date
16 April 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Target lesion failure (TLF)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov